Assessing Ischemic Outcomes with Prasugrel vs. Clopidogrel in ACS: Insights from TRILOGY

Dec 06, 2025

150 likes | 269 Vues

The TRILOGY ACS trial assessed the efficacy of prasugrel compared to clopidogrel for ischemic outcomes in patients with acute coronary syndrome (ACS). Despite enhanced P2Y12 receptor inhibition with prasugrel, the study found no significant difference in ischemic outcomes. This article explores the implications of the results, the challenges in today's trial designs including NIH funding constraints, and the importance of considering exclusion criteria. It highlights the evolution of anticoagulant trials and the need for patient-centered outcomes in future research.

1 acute coronary syndrome 2 p2y12 receptor inhibition 3 prasugrel vs clopidogrel 4 ischemic outcomes 5 trial design challenges 6 patientcentered research 7 nih funding 40 cut 8 anticoagulant trials

delilah-contreras

Télécharger la présentation

Assessing Ischemic Outcomes with Prasugrel vs. Clopidogrel in ACS: Insights from TRILOGY

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D